William Blair analyst Matt Phipps reiterated a Buy rating on Dynavax (DVAX) on June 17. The company’s shares opened today at $3.99, close to its 52-week low of $3.57.
According to TipRanks.com, Phipps has 0 stars on 0-5 star ranking scale with an average return of -20.1% and a 20.0% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics Plc, Kezar Life Sciences Inc, and Atara Biotherapeutics.
Dynavax has an analyst consensus of Strong Buy, with a price target consensus of $23.67, representing a 493.2% upside. In a report issued on June 3, Cowen & Co. also assigned a Buy rating to the stock with a $30 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.35 and a one-year low of $3.57. Currently, Dynavax has an average volume of 1.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.
